Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in ...

The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime in cardiogenic shock targeting data in a similar timeframe WARRINGTON, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ...

A new initiative by The Society for Cardiovascular Angiography & Interventions (SCAI) proposes a new framework and call to action for managing cardiogenic shock (CS), establishing lactate clearance ...

A new initiative by The Society for Cardiovascular Angiography & Interventions (SCAI) proposes a new framework and call to action for managing cardiogenic shock (CS), establishing lactate clearance ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including ...

Just one in three North American patients admitted to the cardiac intensive care unit (CICU) for STEMI complicated by cardiogenic shock (STEMI-CS) would meet the high bar set for entry into the DanGer ...

SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime ...

WASHINGTON–A new initiative by The Society for Cardiovascular Angiography & Interventions (SCAI) proposes a new framework and call to action for managing cardiogenic shock (CS), establishing lactate ...